Global Brugada Syndrome Market Size Envisaged to Reach USD 2.38 Billion By 2032, With a CAGR of 5.7%: Polaris Market Research

New York, NY, May 03, 2023 (GLOBE NEWSWIRE) — Polaris Market Research has published a new research report titled “Brugada Syndrome Market Share, Size, Trends, Industry Analysis Report, By Diagnosis (Electrocardiogram, Electrophysiology test, Genetic testing); By Treatment; By End-Use; By Region; Segment Forecast, 2023 – 2032” in its research database.

“As per the latest research analysis, the global Brugada syndrome market size/share will be valued at roughly USD 1.37 Billion in 2022, and its revenue is projected to reach about USD 2.38 Billion By 2032. The market is forecasted to expand at a compound annual growth rate of approximately 5.7% between 2023 and 2032.”

What is Brugada Syndrome? What is the Expected Market Size of Brugada Syndrome?

Brugada syndrome is an occasional but consequential condition that impacts how electrical signals pass through the heart. It can cause the heart to beat critically fast and can be lethal. The rapidly rising demand for the Brugada syndrome market can be attributed to increased risk factors such as cardiac arrest. If it is not treated instantly, the sudden loss of heart function, breathing, and awareness frequently takes place while sleeping. Appropriate and fast medical care is an answer to this syndrome.

The startling increase in the pervasiveness of heart diseases is the prominent factor driving the market’s growth. Additionally, escalated demand for cure and diagnosis techniques has affirmatively influenced the market. Further, an increase has been observed in the obtainability of diagnostics services for respiratory diseases, which has notably fuelled the market’s growth.

Request Sample Copy of Brugada Syndrome Market Rehttpssearch Report @ https://www.polarismarketresearch.com/industry-analysis/brugada-syndrome-market/request-for-sample

(The sample of this report is readily available on request. The report sample contains a brief introduction to the research report, a Table of Contents, a Graphical introduction of regional analysis, Top players in the market with their revenue analysis, and our research methodology.)

Our Sample Report Covers:

• 2032 Updated Report Introduction, Overview, and In-depth industry analysis.
• 115+ Pages Research Report (Inclusion of Updated Research).
• Provide Chapter-wise guidance on Requests.
• 2023 Updated Regional Analysis with Graphical Representation of Size, Share & Trends
• Includes Updated List of tables & figures.
• Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis.

Some of the Top Market Players Are:

• Abbott
• Boehringer Ingelheim International
• Catalyst Pharmaceuticals Inc
• Ionis Pharmaceuticals
• Leadiant Biosciences Inc
• Natera Inc
• Novo Nordisk A/S
• Pfizer Inc
• PTC Therapeutics
• Roche
• Salarius Pharmaceuticals Inc
• Takeda Pharmaceuticals
• Novartis AG

To Know an Additional List of Key Players, Request Here to Download a Free Report PDF Brochure: https://www.polarismarketresearch.com/industry-analysis/brugada-syndrome-market/request-for-sample

Key data covered in the market report

• The study presents the analytical depiction of the industry along with the current trends and future estimations to determine the imminent investment pockets
• The report presents information related to key drivers, restraints, and opportunities, along with a detailed analysis of the market share
• The current market is quantitatively analyzed to highlight the growth scenario
• Porter’s five forces analysis illustrates the potency of buyers and suppliers in the market
• The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in the coming years

Key factors driving market growth

• Growth in the occurrence of heart failure to push the market

The principal driver of the market is the fact that cardiovascular transplants have extended waiting lists. Because of the growth in heart failure in recent years, the demand for heart transplantation has escalated greatly. Brugada syndrome market size is expanding due to the increasing availability of diagnostic services for respiratory illnesses also fuels the growth of the market.

Several private and government insurance firms are present in developed countries. Over 50 private insurance companies are present in the US. Brugada syndrome market sales are soaring as the policies cover more than 75% of the cost of the devices and treatment. For instance, under the Medicare plan in the US, if the standard price of single chamber devices is roughly USD 10,000, then USD 7,500 is reimbursed. Further, in developed nations such as the UK, Canada, Germany, and others, homogeneous reimbursement policies are available.

Recent trends influencing the market

• Inorganic growth strategies such as partnerships and collaborations to drive the market

Several companies are concentrating on organic growth strategies, which involve product consent, product launches, and others such as events and patents. Inorganic growth strategies highly embraced by key players include partnerships, collaborations, and acquisitions.

The African market for Brugada syndrome displays a balanced growth because of the rise in consciousness about chronic health conditions and the advancement of better healthcare facilities. This region has been observing a prospering growth in the diagnostic devices market and computed tomography and magnetic resonance imaging. As the consciousness about chronic obstructive pulmonary disease in Africa rises, the adequacy of novel therapies is increasing among patients.

Request for a Discount on this Report Before Purchase @ https://www.polarismarketresearch.com/industry-analysis/brugada-syndrome-market/request-for-discount-pricing

Segmentation assessment

• The electrocardiogram diagnosis segment accounted for the major share

Based on the diagnosis, the electrocardiogram diagnosis segment accounted for a major share. Brugada syndrome market demand is rising due to genetic testing being important in recognizing the probability of receiving specific illnesses in screening and, in certain cases, medical treatment. Echocardiography generates images of the heart using sound waves. The test cannot diagnose the syndrome on its own, but it can help in the recognition of structural cardiac issues.

• Implantable cardioverter defibrillator accounted for the fastest-growing segment

Based on treatment, Implantable cardioverter defibrillator accounted for the fastest-growing segment. Brugada syndrome market trends include brugada syndrome being a notable cause of unexpected cardiac mortality in young people. Some medications frequently utilized during the perioperative phase might produce ventricular arrhythmias. 

Inquire more about this report before purchase @ https://www.polarismarketresearch.com/industry-analysis/brugada-syndrome-market/inquire-before-buying

(Inquire about a report quote OR available discount offers to the sales team before purchase.)

Brugada Syndrome Market: Report Scope & Coverage

Geographic Overview

• Growing knowledge about cases of the condition to propel the North American market

North America held the largest brugada syndrome market share due to the rising usage of electrocardiograms, electrophysiology (EP) tests for illness diagnosis, and an extensive populace diagnosed with ailments related to the heart. Additionally, due to the prevalence of a significant number of market contenders manufacturing brugada syndrome drugs and growing knowledge about probabilities and cases of the condition, the US is the largest market in North America.

Browse the Detail Report “Brugada Syndrome Market Share, Size, Trends, Industry Analysis Report, By Diagnosis (Electrocardiogram, Electrophysiology test, Genetic testing); By Treatment; By End-Use; By Region; Segment Forecast, 2023 – 2032” with in-depth TOC: https://www.polarismarketresearch.com/industry-analysis/brugada-syndrome-market  

For Additional Information OR Media Enquiry, Please Mail At: [email protected]

Polaris Market Research has segmented the Brugada market report based on diagnosis, treatment, end-use, and region:

By Diagnosis Outlook

• Electrocardiogram
• Electrophysiology test
• Genetic testing
• Others

By Treatment Outlook

• Implantable cardioverter defibrillator
• Drug Therapy
• Antiarrhythmic Drugs
• Psychotropic Drugs
• Anaesthetics/Analgesics
• Others

By End Use Outlook

• Hospitals and clinics
• Surgical centers
• Diagnostic centers
• Others

By Region Outlook

• North America (U.S., Canada)
• Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
• Asia Pacific (Japan, China, India, Malaysia, Indonesia, South Korea)
• Latin America (Brazil, Mexico, Argentina)
• Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

Browse More Research Reports:

About Polaris Market Research:

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR’s clientele spread across different enterprises. We at Polaris are obliged to serve PMR’s diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR’s customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR’s customers.

Contact:

Likhil G

30 Wall Street

8th Floor,

New York City, NY 10005,

United States

Phone: +1-929 297-9727

Email: [email protected]

Web: https://www.polarismarketresearch.com

Follow Us: LinkedIn | Twitter

Blog: https://polarismarketresearch.medium.com | https://polarisnewsblog.com